Shanghai Xinzhi Biomed Co., Ltd.
Clinical trials sponsored by Shanghai Xinzhi Biomed Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Time gene therapy could free hemophilia patients from frequent infusions Results expected May 2027 (estimated)
-
Brain injection trial hopes to tame Parkinson's
Disease control Recruiting nowThis early-stage study tests whether a new gene therapy called BBM-P002 is safe when injected directly into a specific brain area. It involves 18 adults who have had Parkinson's disease for at least 5 years. The main goal is to check for side effects and see how well the treatmen…
Phase 1 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control Recruiting nowThis trial tests a one-time gene therapy called BBM-H803 for adults with severe hemophilia A. The treatment uses a harmless virus to deliver a working gene to the liver, so the body can produce its own clotting factor VIII. The study involves 55 participants and will check safety…
Phase 2/3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC